Efficacy and toxicity of reirradiation using intensity‐modulated radiotherapy for recurrent or second primary head and neck cancer
David J. Sher(DePaul University), Roy B. Tishler(Dana-Farber Cancer Institute), Lori J. Wirth(Harvard University), Laura A. Goguen(Brigham and Women's Hospital), Donald J. Annino(Harvard University), Charles M. Norris, Robert I. Haddad(Broad Institute), Aaron M. Allen(Tel Aviv University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Tracy A. Balboni(Brigham and Women's Hospital)
Cited by 79
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926